Aura Biosciences, Inc. AURA Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash

Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash at other companies

Summit TherapeuticsSMMT

——

Other financials

Income statement

See full

Operating income-$34.9M-20.1%

Net income-$33.7M-22.6%

EPS (diluted)-$0.50+9.1%

Balance sheet

See full

Cash & equivalents$84.8M+122%

Total debt$17.0M-7.9%

Total equity$107.2M-16.2%

Total assets$137.7M-11.4%

Cash flow

See full

Operating cash flow-$29.9M-28.0%

CapEx$102.0K-45.5%

Free cash flow-$30.0M-27.4%

Valuation

See full

Market cap$709.23M+89.4%

Enterprise value$641.43M+80.8%

Returns & leverage

See full

Return on equity-95.6%+222pp

Debt / equity0.2×0.0×

Current ratio7.1×-4.0×

Where this comes from

Reported directly by Aura Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.

The official record: Aura Biosciences, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aura Biosciences, Inc.'s effect of currency exchange rate changes on cash, cash equivalents, and restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Aura Biosciences, Inc.'s effect of currency exchange rate changes on cash, cash equivalents, and restricted cash?: Aura Biosciences, Inc. (AURA) reported effect of currency exchange rate changes on cash, cash equivalents, and restricted cash of -$27K in Q1 2026.
How has Aura Biosciences, Inc.'s effect of currency exchange rate changes on cash, cash equivalents, and restricted cash changed year-over-year?: Aura Biosciences, Inc.'s effect of currency exchange rate changes on cash, cash equivalents, and restricted cash decreased by 28.6% year-over-year, from -$21K to -$27K.